EUVIMEDEUVIMED entdecken
Crossref

From the Publisher: Fewer Biologics Companies and the Desired Number of New Products Hasn't Materialized

Keith L. Carson

BioProcessing Journal · 27.07.2026 · 6

DOI: 10.12665/j71.kcarson ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioProcessing Journal, online erschienen am 27.07.2026. Verfasst von Keith L. Carson.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Today, thanks to the continued pace of M&As, there are fewer biotech companies, and the desired number of new products just hasn’t materialized. But the real travesty is the loss of the small companies that were creating so many of the highly skilled jobs, and providing the innovation that was driving much of the industry. And what happened to all the displaced workers? Instead of forming partnerships to capitalize on the benefits these small companies had to offer, the acquiring companies had to have it all, or nothing. And unfortunately, too many of them ended up with nothing...

Zitieren

APA

Carson, K. L. (2026). From the Publisher: Fewer Biologics Companies and the Desired Number of New Products Hasn't Materialized. BioProcessing Journal, 6. https://doi.org/10.12665/j71.kcarson

Vancouver

Carson KL. From the Publisher: Fewer Biologics Companies and the Desired Number of New Products Hasn't Materialized. BioProcessing Journal. 2026:6. doi:10.12665/j71.kcarson

BibTeX
@article{Carson2026,
  author = {Carson, Keith L.},
  title = {From the Publisher: Fewer Biologics Companies and the Desired Number of New Products Hasn't Materialized},
  journal = {BioProcessing Journal},
  year = {2026},
  pages = {6},
  doi = {10.12665/j71.kcarson}
}
Kostenlos starten →